Publications

S1P5

Sphingolipid Metabolism: A New Therapeutic Opportunity for Brain Degenerative Disorders.
Frontiers in Neuroscience.

DiPardo, A., Maglione, V. (2018).

Sphingosine-1-phosphate receptor therapies: Advances in clinical trials for CNS-related diseases.
O’Sullivan, S., Dev, KK. (2017). Neuropharmacology. 113, 597-607.

The Role of Ceramide and Sphingosine-1-Phosphate in Alzheimer’s Disease and Other Neurodegenerative Disorders.
Czubowicz, K., Jęśko, H., Wencel, P., Lukiw, WJ., Strosznajder, RP. (2019) Mol Neurobiol. 56, 5436-5455.

LRRK2

Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease.
West, AB. (2017). Exp Neurol. 298, 236-245.

LRRK2 inhibitors and their potential in the treatment of Parkinson’s disease: current perspectives.
Atashrazm, F., Dzamko, N. (2016) Clin Pharmacol. 8, 177-189.

Disease Penetrance of Late-Onset Parkinsonism: A Meta-analysis.
Trinh, J., Guella, I., Farrer, M. (2014) JAMA Neurol. 71, 1535-1539.

LRRK2 exonic variants associated with Parkinson’s disease augment phosphorylation levels for
LRRK2-Ser1292 and Rab10-Thr73.

Christensen, K. (2018) BioRxiv.

ApoE4

Apolipoprotein E and Alzheimer disease: risk, mechanisms, and therapy.
Liu, C.C., Kanekiyo, T., Xu, H., and Bu, G. (2013). Nat. Rev. Neurol. 9, 106–118.

Apolipoprotein E sets the stage: response to injury triggers neuropathology.
Mahley, R.W., Huang, Y. (2012). Neuron 76, 871-885.

Roles of apolipoprotein E in Alzheimer’s Disease and other neurological disorders.
Verghese, P.B., Castellano, J.M., and Holtzman, D.M. (2011). Lancet Neurol. 10, 241–252.

Longitudinal modeling of age-related memory decline and the ApoE Ɛ4 effect.
Caselli, R.J., Dueck, A. C., Osborne, D., Sabbagh, M.N., Connor, D.J., Ahern, G.L., Baxter, L.C., Rapcsack,
S.Z., Shi, J., Woodruff, B.K., et al. (2009). N. Engl. J. Med. 361, 255-263.

ApoE genotype accounts for the vast majority of AD risk and AD pathology.
Raber, J., Huang, Y., Ashford, J.W. (2004). Neurobiol. Aging 25, 641-650.